Antibodiesinc/TrpC1/75-278/1 Ea
商品编号：
75-278
市场价：
¥0.00
美元价：
0.00
产品分类：
重组抗体
公司分类：
Recombinant_antibodies
联系Q Q：
3392242852
电话号码：
4000-520-616
电子邮箱：
info@ebiomall.com
商品介绍
Immunogen:
Fusion protein amino acids 27-306 (cytoplasmic N-terminus) of human TRPC1 (also known as Short transient receptor potential channel 1, Transient receptor potential cation channel subfamily C member 1, Transient receptor protein 1, TRP1, Trp-related protein 1 and Trrp1, accession number P48995)
Mouse: 99% identity (279/280 amino acids identical)
Rat: 99% identity (278/280 amino acids identical)
>50% identity with TRPC4
Hybridoma kindly donated by Dr. Leonidas Tsiokas, University of Oklahoma Health Sciences Center (2003 Ma et al JBC, PMID 14530267).
This NeuroMab antibody is considered "Restricted" and is therefore not available for commercial re-distribution on a for-profit basis.
Mouse: 99% identity (279/280 amino acids identical)
Rat: 99% identity (278/280 amino acids identical)
>50% identity with TRPC4
Hybridoma kindly donated by Dr. Leonidas Tsiokas, University of Oklahoma Health Sciences Center (2003 Ma et al JBC, PMID 14530267).
This NeuroMab antibody is considered "Restricted" and is therefore not available for commercial re-distribution on a for-profit basis.
Specifications:
Target |
|
TrpC1 |
|
|
||
Channel Target |
|
Trp Channels |
|
|
||
Applications |
|
Immunoblot (IB) Immunocytochemistry (ICC) |
|
|
||
Clone |
|
1F1 |
|
|
||
IgG Isotype |
|
IgG1 |
|
|
||
Species Reactivity |
|
Human (H) Mouse (M) Rat (R) |
|
|
||
Validation |
|
Br-IB KO T |
|
|
||
Type |
|
Purified |
|
|
||
Format |
|
100 ul |
|
|
||
Cross Reactivity |
|
Does not cross-react with TRPC4 (based on KO validation results) |
|
|
||
Expected Banding Pattern |
|
80-90 kDa |
|
|
||
Host |
|
Mouse (M) |
|
|
||
Label |
|
Unlabeled |
|
|
||
Antibody Type |
|
Monoclonal |
|
|
||
Commercial Price |
|
450 |
|
|
||
Non-Profit Price |
|
200 |
|
|
||
Distributor Price |
|
Per Contract(QUOTE) |
|
|
||
ABID |
|
RRID:AB_2315951 |
|
|
||
品牌介绍
当抗体公司（Antibodies Incorporated）在1962年开业时，与抗体相关的研究才刚刚开始。创始人Jim Hillman拥有博士学位。从药理学明尼苏达大学，来到加州大学戴维斯分校在免疫化学完整的博士后工作，在工作期间，他学习了加州理工学院（加州理工学院）根据丹·坎贝尔，领域的先驱。吉姆带来了他的妻子，公司的共同创始人卡罗尔（Carol）和两个孩子，以及使用基于抗体的化学疗法寻找治疗癌症的能量和想法。具体地说，吉姆认为，如果他能够识别并分离出可能具有抗原性的肿瘤部位（一个焦点是淋巴肉瘤），则可能有可能进行有效的基于抗体的治疗。吉姆寻找这种治疗方法的梦想推动了他的工作多年。
